Sponsored genetic testing programs can run afoul of federal laws, including the FCA and AKS, if not designed correctly.

New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must ...

The onset of the new U.S. presidential administration brings with it sweeping changes to U.S. policy related to artificial intelligence (AI). As a first step, the Trump administration revoked the ...

Oxygen, crucial for cellular respiration, is affected by pressure variations within a bioreactor, with higher pressure at the bottom leading to increased oxygen solubility. This heterogeneity is ...

In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies ...

Tom Chalberg, Ph.D., co-founder of Genascence, explains how gene therapies are moving beyond the confines of rare diseases and into a wider range of indications.

CEO Peter Anastasiou describes the science behind Capsida’s platform, current pipeline, and why they chose to manufacture in-house.

In the dynamic pharmaceutical industry, successful product launches are critical to business success. For small and midsized biotech firms, where the reliance on a few key assets is high, the stakes ...

Over the last 15 years, biopharmaceutical compliance departments, and chief compliance officers, have been better resourced, with more direct reporting lines to company leadership, than ever before. A ...